Vanda Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 203
- Market Cap
- $311.8M
- Introduction
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The ...
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 152
- Registration Number
- NCT02970968
- Locations
- 🇺🇸
Vanda Investigational Site, Norfolk, Virginia, United States
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2016-05-18
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02776215
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT02651714
- Locations
- 🇺🇸
Vanda Investigational Site, Spokane, Washington, United States
Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT02621385
- Locations
- 🇨🇭
Vanda Investigational Site, Arzo, Switzerland
An Observational Study to Investigate the Effects of Rapid Transmeridian Travel
- Conditions
- Interventions
- First Posted Date
- 2015-09-25
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 119
- Registration Number
- NCT02560103
- Locations
- 🇺🇸
The Center for Sleep & Wake Disorders, Chevy Chase, Maryland, United States
🇺🇸Santa Monica Clinical Trials, Santa Monica, California, United States
Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 49
- Registration Number
- NCT02231008
Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)
- Conditions
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2016-03-25
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02180451
Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)
- Conditions
- Interventions
- First Posted Date
- 2014-05-06
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT02130999
Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis
- Conditions
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 69
- Registration Number
- NCT02004041
- Locations
- 🇩🇪
Vanda Investigational Site, Munster, Germany
Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P
- First Posted Date
- 2013-08-09
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Vanda Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT01919944
- Locations
- 🇨🇭
Vanda Investigational Site, Arzo, Switzerland